Experience

Davis Polk advised Roche Holdings, Inc. in connection with a cash tender offer for up to $250 million aggregate principal amount of its 7.00% notes due 2039. Headquartered in Basel,…

Davis Polk advised the joint book-running managers in connection with the $100.9 million public offering of common stock of Achaogen, Inc. The common stock is listed onthe NASDAQ Global…

Davis Polk advised the sole placing agent in connection with the placing of 38,500,000 shares held by China Asset Management Co., Ltd. in Yestar International Holdings Company Limited for a…

Davis Polk advised the sole book-running manager in connection with the $126.5 million public offering of common stock of Xencor, Inc. The common stock is listed on the NASDAQ Global Market…

Davis Polk advised the initial purchasers in connection with a Rule 144A offering by Evolent Health, Inc. of $125 million aggregate principal amount of its 2.00% senior convertible notes…

Davis Polk advised the joint book-running managers on an SEC-registered offering by Abbott Laboratories of $2.85 billion aggregate principal amount of 2.350% notes due 2019, $2.85 billion…

Davis Polk advised the representatives of the underwriters in connection with an SEC-registered offering by AbbVie Inc. of €3.6 billion aggregate principal amount of senior notes in three…

Davis Polk advised the representatives of the underwriters, in connection with the offering of €1 billion aggregate principal amount of notes issued by Merck & Co., Inc. The notes were…

Davis Polk advised the joint book-running managers in connection with a $100.1 million SEC-registered offering of 3,850,000 ordinary shares of Theravance Biopharma, Inc. The ordinary…

Davis Polk advised Roche Holdings, Inc. in connection with its Rule 144A/Regulation S offering of $650 million aggregate principal amount of 1.750% notes due 2022 and $850 million aggregate…